These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 21549780)

  • 1. Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.
    Minke JM; Siger L; Cupillard L; Powers B; Bakonyi T; Boyum S; Nowotny N; Bowen R
    Vaccine; 2011 Jun; 29(28):4608-12. PubMed ID: 21549780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse.
    El Garch H; Minke JM; Rehder J; Richard S; Edlund Toulemonde C; Dinic S; Andreoni C; Audonnet JC; Nordgren R; Juillard V
    Vet Immunol Immunopathol; 2008 Jun; 123(3-4):230-9. PubMed ID: 18372050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Cross-Protection of a Lineage 1 West Nile Virus Inactivated Vaccine against Natural Infections from a Virulent Lineage 2 Strain in Horses, under Field Conditions.
    Chaintoutis SC; Diakakis N; Papanastassopoulou M; Banos G; Dovas CI
    Clin Vaccine Immunol; 2015 Sep; 22(9):1040-9. PubMed ID: 26178384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model.
    Long MT; Gibbs EP; Mellencamp MW; Bowen RA; Seino KK; Zhang S; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):491-7. PubMed ID: 18065305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the efficacy provided by a Recombinant Canarypox-Vectored Equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses.
    Siger L; Bowen R; Karaca K; Murray M; Jagannatha S; Echols B; Nordgren R; Minke JM
    Vet Ther; 2006; 7(3):249-56. PubMed ID: 17039448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model.
    Seino KK; Long MT; Gibbs EP; Bowen RA; Beachboard SE; Humphrey PP; Dixon MA; Bourgeois MA
    Clin Vaccine Immunol; 2007 Nov; 14(11):1465-71. PubMed ID: 17687109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge.
    Karaca K; Bowen R; Austgen LE; Teehee M; Siger L; Grosenbaugh D; Loosemore L; Audonnet JC; Nordgren R; Minke JM
    Vaccine; 2005 May; 23(29):3808-13. PubMed ID: 15893618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine.
    Grosenbaugh DA; Backus CS; Karaca K; Minke JM; Nordgren RM
    Vet Ther; 2004; 5(4):251-7. PubMed ID: 15719324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equine vaccine for West Nile virus.
    Ng T; Hathaway D; Jennings N; Champ D; Chiang YW; Chu HJ
    Dev Biol (Basel); 2003; 114():221-7. PubMed ID: 14677692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of horses from West Nile virus Lineage 2 challenge following immunization with a whole, inactivated WNV lineage 1 vaccine.
    Bowen RA; Bosco-Lauth A; Syvrud K; Thomas A; Meinert TR; Ludlow DR; Cook C; Salt J; Ons E
    Vaccine; 2014 Sep; 32(42):5455-9. PubMed ID: 25131745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice.
    Venter M; van Vuren PJ; Mentoor J; Paweska J; Williams J
    Vaccine; 2013 Aug; 31(37):3856-62. PubMed ID: 23820079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing antibody response against West Nile virus (WNV).
    Rosas CT; Tischer BK; Perkins GA; Wagner B; Goodman LB; Osterrieder N
    Virus Res; 2007 Apr; 125(1):69-78. PubMed ID: 17241683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
    Minke JM; Siger L; Karaca K; Austgen L; Gordy P; Bowen R; Renshaw RW; Loosmore S; Audonnet JC; Nordgren B
    Arch Virol Suppl; 2004; (18):221-30. PubMed ID: 15119777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of red-legged partridges (Alectoris rufa) against West Nile virus (WNV) infection after immunization with WNV recombinant envelope protein E (rE).
    Escribano-Romero E; Gamino V; Merino-Ramos T; Blázquez AB; Martín-Acebes MA; de Oya NJ; Gutiérrez-Guzmán AV; Escribano JM; Höfle U; Saiz JC
    Vaccine; 2013 Sep; 31(41):4523-7. PubMed ID: 23933372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis.
    Desprès P; Combredet C; Frenkiel MP; Lorin C; Brahic M; Tangy F
    J Infect Dis; 2005 Jan; 191(2):207-14. PubMed ID: 15609230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.
    Liu SA; Haque M; Stanfield B; Andrews FM; Roy AA; Kousoulas KG
    Vet Microbiol; 2017 Jan; 198():51-58. PubMed ID: 28062007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.
    Schneeweiss A; Chabierski S; Salomo M; Delaroque N; Al-Robaiy S; Grunwald T; Bürki K; Liebert UG; Ulbert S
    Vaccine; 2011 Aug; 29(37):6352-7. PubMed ID: 21596075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of an attenuated West Nile virus vaccine, live Flavivirus chimera in horses.
    Long MT; Gibbs EP; Mellencamp MW; Zhang S; Barnett DC; Seino KK; Beachboard SE; Humphrey PP
    Equine Vet J; 2007 Nov; 39(6):486-90. PubMed ID: 18065304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine.
    Davis EG; Zhang Y; Tuttle J; Hankins K; Wilkerson M
    Vet Immunol Immunopathol; 2008 Dec; 126(3-4):293-301. PubMed ID: 18838173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
    Minke JM; Fischer L; Baudu P; Guigal PM; Sindle T; Mumford JA; Audonnet JC
    Vet Immunol Immunopathol; 2006 May; 111(1-2):47-57. PubMed ID: 16580075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.